期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Preserving fertility in the hypogonadal patient: an update 被引量:4
1
作者 Ranjith Ramasamy Joseph M Armstrong Larry I Lipshultz 《Asian Journal of Andrology》 SCIE CAS CSCD 2015年第2期197-200,I0006,I0007,共6页
An increasing number of young and middle-aged men are seeking treatment for symptoms related to deficient levels of androgens (hypogonadism) including depression, loss of libido, erectile dysfunction, and fatigue. T... An increasing number of young and middle-aged men are seeking treatment for symptoms related to deficient levels of androgens (hypogonadism) including depression, loss of libido, erectile dysfunction, and fatigue. The increase in prevalence of testosterone supplementation in general and anabolic steroid-induced hypogonadism specifically among younger athletes is creating a population of young men who are uniquely impacted by the testicular end-organ negative consequences of exogenous steroid use. Exogenous testosterone therapy can alter the natural regulation of the hypothalamic-pituitary-gonadal axis leading to impaired spermatoganesis with azoospermia being a serious possible result, thus rendering the individual infertile. For men of reproductive age who suffer from hypogonadal symptoms, preservation of fertility is an important aspect of their treatment paradigm. Treatment with human chorionic gonadotropin (hCG) has shown the ability not only to reverse azoospermia brought on by testosterone supplementation therapy but also to help maintain elevated intratesticular testosterone levels. In addition, selective estrogen receptor modulators, often used with hCG have been shown both to elevate total testosterone levels and to maintain spermatogenesis in hypogonadal men. 展开更多
关键词 human chorionic gonadotropin selective estrogen receptor modulators SPERMATOGENESIS testosterone supplementation therapy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部